Regain

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regain

Property Description
Active ingredient Minoxidil
Form Topical solution, Cutaneous foam
Pharmacological class Hair growth stimulant, Peripheral vasodilator
Common use Addressing pattern hair loss (Androgenetic alopecia)
Origin Synthetic compound

What Type of Medicine is Regain and What is its Classification?

Regain is a non-prescription (Over-the-Counter) dermatological medicine that contains the active ingredient Minoxidil. It is classified primarily as a hair growth stimulant and a peripheral vasodilating agent. The designation as a peripheral vasodilator reflects Minoxidil's original development as an oral antihypertensive agent.

As a synthetic pharmaceutical preparation, Regain's identity is rooted in its pharmacological action, which distinguishes it from cosmetic scalp treatments. The product is intended for topical administration directly to the scalp. This classification establishes it as a scientifically researched product designed to physiologically influence the hair growth process, offering a general therapeutic purpose for individuals experiencing certain types of progressive hair thinning, specifically androgenetic alopecia or pattern hair loss, a condition clinically recognized by dermatologists as hereditary hair thinning.


Regain's Composition and Available Forms

The therapeutic effect of Regain is delivered solely by Minoxidil, a synthetic compound that is a derivative of piperidinopyrimidine. This preparation is a single active ingredient product, where Minoxidil serves as the active substance in dermatological formulations for this indication.

Regain is available in two main dosage forms for cutaneous use: a clear topical solution and a lighter, quick-drying cutaneous foam. The formulations utilize a base or vehicle, such as an ethanolic or aerosol base, engineered for efficient delivery of Minoxidil to the hair follicles on the scalp, offering patients a choice based on application preference.


What is the General Purpose of Regain?

The overall general purpose of Regain is to help support and encourage the growth of existing hair in affected areas of the scalp. The medicine achieves this by working at a high physiological level to help revitalize and increase the size of miniaturized hair follicles.

Minoxidil acts by promoting the prolongation of the anagen phase—the natural active growth period of the hair. This action links the drug's properties directly to the goal of mitigating the appearance of hereditary baldness by sustaining and promoting follicle development, making it a common choice in general therapeutic regimens for pattern hair loss.

What side effects are possible with Regain?

Official Safety Profile of Regain (Topical Minoxidil)

The official safety profile for topical minoxidil (Regain) is primarily structured around localized reactions and the potential for systemic effects due to its peripheral vasodilator properties. All reported adverse reactions are classified by frequency according to regulatory standards.


Frequency-Classified Adverse Reactions

Classification Examples (Organ Class)
Very Common (ge 1/10) Headache (Nervous System)
Common (ge 1/100 to < 1/10) Hypertrichosis, Pruritus, Dermatitis (Skin); Peripheral Oedema (General Disorders)
Uncommon (ge 1/1,000 to < 1/100) Dizziness, Nausea (Nervous/GI); Palpitations (Cardiac)
Rare (< 1/10,000) Chest pain, Tachycardia (Cardiac)

Serious Adverse Reactions and Safety Constraints

The most commonly encountered adverse events relate to Skin and Subcutaneous Tissue Disorders, including irritation, dry skin, and unwanted hair growth (Hypertrichosis). An initial temporary increase in hair shedding may be observed early in the treatment period, generally resolving within a few weeks.

Serious adverse reactions are related to systemic absorption of the active ingredient, resulting in potential Cardiovascular Disorders. These reactions, which require immediate discontinuation of the product, include officially documented instances of chest pain, rapid heartbeat (Tachycardia), faintness, and swelling of the hands or feet (Oedema).

Regulatory safety information notes that safety and efficacy have not been established in individuals under 18 years of age. The product should also not be applied to a scalp that is damaged, irritated, or inflamed, as this may increase systemic absorption.

Overdose and Emergency Response

The official documentation for Minoxidil topical focuses on the potential for systemic effects if the medicine is absorbed in excessive amounts or accidentally ingested. Overdose manifestations are related to the drug's potent vasodilating properties, which can result in significant effects on the cardiovascular system.

Documented systemic signs that necessitate medical attention include symptoms of low blood pressure, such as dizziness, light-headedness, and faintness. More serious cardiovascular manifestations listed in regulatory labeling are tachycardia (rapid heartbeat) and the occurrence of chest pain.

Overdose may also present with signs of fluid imbalance, notably sudden, unexplained weight gain and swollen hands or feet (edema). These signs are regulator-mandated triggers for seeking medical help.

In the event of accidental ingestion, particularly by a young child, the risk of severe systemic toxicity and cardiovascular collapse is high. For any ingestion, the explicit instruction from regulatory bodies is to seek immediate medical attention or contact a Poison Control Center. If any of the above systemic signs occur during topical use, the labeling requires the patient to stop using the product and see a doctor immediately. Treatment is supportive, and no specific antidote is known.

Therapeutic Uses of Regain

What Regaine Treats: Main Uses and Benefits

Regaine (minoxidil topical solution or foam) is commonly used across conditions presenting with acute episodes of a specific pattern of hair loss. This primarily involves androgenetic alopecia (male- or female-pattern hair loss), which is characterized by gradual hair thinning and loss on the scalp. This topical medication is relevant for managing symptoms that interfere with daily comfort. The product provides support that helps ease the overall symptom burden associated with hair thinning and visible hair loss, which are key symptoms related to physical discomfort. It is generally applied in scenarios where additional management of the functional strain from hair loss is needed.

Quick Fact: Supports management of Symptoms related to physical discomfort

The use of minoxidil topical may assist with maintaining a sense of stability when symptoms are more noticeable. The overall approach generally supports general well-being during symptomatic phases:

“The medication is commonly used to help with symptoms that create noticeable functional strain and contributes to easing the overall symptom load.”

Continued application may be part of symptomatic management to help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview on Minoxidil Topical

Eligibility and Restrictions for Use

Eligibility for Regain (Minoxidil Topical)

Official regulatory documents define strict population parameters for using Regain, which contains the active ingredient Minoxidil. Use is permitted only for adults between 18 and 65 years of age who are experiencing Androgenetic Alopecia (pattern hair loss).

Population Group Regulatory Status
Core Age Group Approved for use in adults 18 to 65 years [MHRA - SmPC].
Pediatric Use Not recommended for those under 18 years; safety and efficacy are not established [EMA - SmPC].
Older Adults Not recommended for those over 65 years; safety and efficacy are not established [FDA - DailyMed Label].

Contraindications and Restrictions

Regain is formally contraindicated and must not be used by several population groups, primarily due to the risk of systemic absorption or localized adverse reactions. These exclusions include:

  • Patients with hypersensitivity or allergy to Minoxidil or any excipients.
  • Individuals with a scalp that is red, inflamed, infected, irritated, or painful [FDA - DailyMed Label].
  • Women who are pregnant or breastfeeding are not recommended to use the product [HPRA - SmPC].
  • Patients with known cardiovascular disease or cardiac arrhythmia should seek medical consultation before use due to the potential for systemic effects [EMA - SmPC].

These official eligibility rules restrict use to the specific adult demographic for which safety and efficacy have been established and prohibit use in populations with pre-existing risk factors or insufficient data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for topical Minoxidil (Regain) defines interactions based on local application restrictions, altered absorption, and the potential for systemic effects.

Classification Interaction Context
Local Co-administration Prohibition of use with any other medicine on the scalp.
Procedural Constraint Must not be applied 24 hours before or after chemical hair treatments (e.g., coloring or permanents).
Systemic Risk Theoretical potentiation of orthostatic hypotension when combined with systemic peripheral vasodilators (e.g., Guanethidine).

Documented Pharmacokinetic and Effectiveness Alterations

Co-administration with specific topical agents is officially documented to modify the amount of Minoxidil absorbed into the body, primarily due to changes in skin permeability:

  • Increased Systemic Exposure: Topical agents such as Tretinoin or Anthralin are known to enhance the percutaneous absorption of Minoxidil, thereby increasing systemic exposure.
  • Decreased Systemic Exposure: Topical Betamethasone Dipropionate is documented to decrease the amount of Minoxidil absorbed systemically.
  • Reduced Effectiveness: Systemic use of Low-Dose Acetylsalicylic Acid (Aspirin) may interfere with the sulfotransferase enzyme required to convert Minoxidil to its active form, potentially diminishing the medicine’s effectiveness.

Population-Specific Note

Minoxidil that is systemically absorbed is known to distribute into human milk, which necessitates regulatory caution regarding potential exposure to nursing infants.

Mechanism of Action

How Regain Works: Mechanism of Action

Regain's mechanism of action involves the induction of cellular regeneration. It engages a sequence of molecular events that result in the creation of new sensory cells within the auditory system.


Key Pathway: Inhibition of Notch Signaling

Regain functions as a gamma-secretase inhibitor, targeting this enzyme complex primarily in the inner ear. By blocking the activity of gamma-secretase, Regain prevents the necessary cleavage of the Notch receptor, thereby shutting down the Notch signaling pathway in cochlear supporting cells. This interaction provides the molecular signal to initiate cellular regeneration.


Core Effect: Activation of Sensory Cell Regeneration

This mechanistic domain describes the resulting physiological consequence of pathway inhibition. Suppressing the restrictive Notch signal activates surrounding supporting cells to undergo differentiation. This process leads to the formation of new auditory sensory hair cells, contributing to the inner ear's structural capacity for sound transduction.

Dosage and Administration Information

How Regain is Used

Regain (Minoxidil topical) is a dermatological medicine whose application follows specific instructions to ensure standardized use for pattern hair loss.

Administration Scope and Dosage

The medicine is solely administered via the topical route directly to the scalp. Dosing is distinguished based on formulation and sex, but in all cases, the daily application amount should not exceed 2 mL of solution.

Population Form / Strength Application Schedule
Adult Men 5% Solution or Foam 1 mL or half a capful twice daily
Adult Women 2% Solution 1 mL twice daily
Adult Women 5% Foam Half a capful once daily

Procedural and Duration Requirements

For proper administration, the product must be applied only to a completely dry scalp. Following application, the medicine should be allowed to dry for two to four hours to prevent transfer, particularly before sleep. If a scheduled dose is missed, instructions advise continuing with the next dose and not using extra medicine to compensate. Continuous use is defined as the required pattern of administration, as any hair growth achieved may be lost within a few months of discontinuing treatment. Use is generally not recommended for individuals under 18 or over 65, as data on safety and efficacy in these groups are limited.

These standardized protocols define the required method and duration of the treatment course.

Recent Clinical Evidence

Research Evidence for Androgenetic Alopecia (Pattern Hair Loss)

The core research that supports the use of topical Minoxidil (Regain) consists of Randomized Controlled Trials (RCTs). These short- to intermediate-term studies are a key type of evidence where subjects with pattern hair loss are randomly assigned to receive either the topical product or a non-active control (a placebo) to allow researchers to measure and observe any differences between the groups. These trials were used in research exploring how symptoms related to hair thinning change over time.

Research primarily focused on adult men and women diagnosed with mild to moderate pattern hair loss. Research examined outcomes related to hair structure and density. Researchers examined variables such as hair count in specific target areas of the scalp. Other measures included evaluation of hair thickness and global assessments made by physicians regarding the overall change in hair characteristics over the study period.

Research highlights changes measured during the study period over intermediate follow-up periods, typically ranging from 4 to 12 months. These studies report how symptoms related to visible hair thinning evolved in the observed populations. Physician reports often described a measurable difference in the outcomes examined when comparing subjects using the product versus those using the placebo. These findings help contextualize how patients reported their experience in studies observing responses over defined time intervals.


What Remains Unclear or Under-Researched

A key area where certainty remains low involves the variability of response among individuals. While study results reflect the specific conditions under which they were conducted, research highlights that a subset of subjects in the clinical trials showed minimal or no measurable change, and clear factors for predicting individual outcomes are not universally established.

Additionally, comparative evidence is lacking for certain formulations or strengths over the long term. Data related to the durability and sustained maintenance of hair characteristics beyond the typical one-year study period is also an area where more research is needed to fully understand the long-term effects of continuous use. Research provides context but not individual predictions regarding these uncertainties.

Key Studies & References

  1. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men (Olsen et al., 2002)
  2. Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled trials (Park et al., 2025)
  3. Public Assessment Report National Procedure Minoxidil 5% cutaneous solution (MHRA) – Well-Established Use (Regulatory Documentation)

Frequently Asked Questions (FAQ)

Common questions about Regain (FAQ)

Q: What is the main difference between Regain and other similar medicines?

A: Regain contains the active ingredient Minoxidil, which is officially classified as both a hair growth stimulant and a peripheral vasodilating agent for topical use. This scientific designation reflects its specific function to promote hair growth in the scalp. This pharmacological classification is what distinguishes it from non-medicated or cosmetic products.


Q: Are there any rare but serious side effects associated with Regain?

A: Official safety profiles document adverse reactions according to frequency, including those classified as Rare (occurring in less than 1 in 10,000 users). These documented reactions may include systemic effects like chest pain and rapid heartbeat (tachycardia) due to the potential for the medicine to be absorbed into the body. These effects are noted in regulatory information as reasons to discontinue the product.


Q: Can Regain affect my mood or sleep?

A: Official safety data classifies certain nervous system reactions, such as dizziness or headache. However, specific effects on an individual's mood or typical sleep disturbances are generally not listed as commonly classified adverse reactions in the official documents for the topical formulation.


Q: Does Regain interact with common pain relievers like Tylenol or Advil?

A: Official interaction summaries highlight that systemic use of Low-Dose Acetylsalicylic Acid (Aspirin) may potentially interfere with the medicine's conversion to its active form. Other common non-aspirin pain relievers like acetaminophen or ibuprofen are typically not explicitly mentioned in the core interaction documentation.


Q: Why do some users report a change in appetite when using Regain?

A: Official safety profile documentation does classify nausea as an uncommon adverse reaction associated with use. While nausea can sometimes be related to changes in eating habits, official documents do not explicitly classify a specific change in appetite itself among the commonly reported side effects.


Q: Is Regain known to cause weight changes?

A: Official safety information includes Peripheral Oedema (swelling of the hands or feet due to fluid retention) as a common adverse reaction. Separately, sudden unexplained weight gain is noted in regulatory information as a systemic side effect that may warrant discontinuing the product.


Q: Why do people say Regain is used for a wide range of conditions?

A: The active ingredient in Regain, Minoxidil, was originally developed and approved as an oral medicine for high blood pressure, where it functions as a peripheral vasodilating agent. This historical use for a vascular condition is distinct from its current, approved topical use for pattern hair loss.


Q: Does Regain start working right away?

A: Official product information indicates that observable hair regrowth is not immediate. Observable results may require continuous use for at least four months before initial changes may be observed. This reflects the natural cycle of hair growth.


Q: How long do the effects of Regain last?

A: Official guidelines state that any hair growth achieved may be lost within a few months if continuous treatment is stopped. Furthermore, research summaries note that more data is needed to fully understand the long-term durability and sustained maintenance of hair characteristics beyond the typical one-year study period.


Q: Is it normal to feel tired or dizzy when starting Regain?

A: Official safety documentation classifies dizziness as an uncommon adverse reaction associated with use. Separately, tiredness is also noted in regulatory information as a systemic effect that may warrant discontinuing the product.


Q: How does Regain generally affect driving or operating machinery?

A: Regulatory patient information sheets often note that the medicine has the potential to cause side effects such as dizziness or low blood pressure. Regulatory information advises that if these reactions occur, individuals should avoid driving or operating machinery.


Q: Is Regain habit-forming or a controlled substance?

A: According to official drug fact sheets, the active ingredient Minoxidil is classified as Not a controlled medication. Therefore, it is not considered to be habit-forming or to have a potential for abuse or dependence.


Q: Is the generic version of Regain available, and is it the same?

A: Yes, the U.S. Food and Drug Administration (FDA) has approved generic versions of Minoxidil topical formulations. The agency determined these generics to be therapeutically equivalent to the brand-name product for the approved indication.


Q: Are there specific demographics that tend to see better results from Regain?

A: Official research documentation highlights that clinical trials found a variability of response among individuals using the product. Regulatory summaries note that clear factors for predicting how any single person will respond are not universally established, and official information cautions against using this data to make individual predictions.


Q: What is the typical timeframe before knowing if Regain is the right fit?

A: Official labeling suggests that the initial period for evaluation is generally four months of continuous, correct use. If observable hair regrowth is not noticed by the end of this period, regulatory information advises seeking consultation from a healthcare professional.


Q: How common is the initial headache reported with Regain?

A: Official safety profiles classify headache as a Very Common adverse reaction associated with the use of the medicine. This frequency classification means it is reported in at least 1 out of every 10 people in clinical trials.


Q: What does the FDA say about the safety profile of Regain?

A: The official safety profile for the active ingredient, Minoxidil, is synthesized from regulatory documentation, including the U.S. FDA’s DailyMed label and similar European agency records. These documents provide the comprehensive, factual list of documented side effects, safety constraints, and warnings.

How should Regain be stored and disposed of?

The official storage and disposal requirements for Regain are defined by its formulation as a topical, flammable product requiring strict temperature and handling controls.

Official Storage and Disposal Statements

  • Temperature Control: Store at controlled room temperature 20^circ to 25^circ C (68^circ to 77^circ F). The product must be kept from freezing and protected from excess heat.
  • Flammability: Both the solution and foam are labeled as flammable; therefore, they must be kept away from fire, flame, and all ignition sources.
  • Container Rules (Foam): The pressurized foam container must not be punctured or incinerated and should not be exposed to temperatures exceeding 120^circ F (49^circ C).
  • Child Safety: The medication must be kept in its tightly closed container, out of reach of children, as accidental ingestion carries a risk of serious adverse cardiac events.
  • Disposal: Unused or outdated product must be disposed of in accordance with local regulatory requirements. Medicines should not be disposed of via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Regain found in:

A-Z Index: